GBV-C/HGV is a newly described hepatitis virus belonging to the Flaviviridae family. The virus has a genome organisation similar to that of hepatitis C virus (HCV) with which it shares 25% identity at the nucleotide level. Probably, it is causative agent of non A-non E hepatitis and it is readily transmitted by blood transfusions, by some blood products, by parenteral exposure to blood during intravenous drug use and haemodialysis. In this study, we have investigated HGV prevalence in a group of blood donors, hepatopatic patients and intravenous drug users, according to different clinical-virological markers. Total RNA extracted from plasma samples was amplified by RT-PCR using specific primers for the 5' untranslated region (5'-UTR) and the 3-A non structural region (NS3) of the HGV genome. Using an enzyme immunoassay, we tested in the same samples the seroprevalence of antibodies to HGV envelope protein (anti-E2). The results are in accordance with known ones even if the pathological significance of HGV infection remains unelucidated. So, we propose to perform a patients follow-up and investigate biopsy by molecular techniques in order to elucidate the role of HGV in hepatic disease.
|Translated title of the contribution||Prevalence of HGV RNA and anti-E2 in a group of blood donors, in patients with liver diseases and in intravenous drug users|
|Number of pages||5|
|Journal||Trasfusione del Sangue|
|Publication status||Published - 1999|
ASJC Scopus subject areas
- Immunology and Allergy